L-DOPA-induced neurotoxic and apoptotic changes on cultured chromaffin cells

NeuroReport

Volumn 11, Issue 3, 2000, Pages 503-506

  Corona Morales, Aleph A ^a   Castell, Andrés ^a   Zhang, Limei ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Apoptosis; Chromaffin cells; L DOPA; MTT; Neurotoxicity; Parkinson's disease; TUNEL; Tyrosine hydroxylase

Indexed keywords

ANTIOXIDANT; LEVODOPA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL STRUCTURE; CELL TRANSPLANTATION; CHROMAFFIN CELL; CONTROLLED STUDY; CYTOCHEMISTRY; DRUG EFFECT; MALE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0033996570     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200002280-00015     Document Type: Article

References (22)

1. Bernheimer H, Birkmayer W, Hornykiewicz O et al. J Neurol Sci 20, 415-455 (1973).
2. Burke RE. Parkinson's disease. In: Koliatsos VE and Ratan RR eds. Cell Death and Disease of The Nervous System. New Jersey: Humana Press, 1999: 459-475.
3. Jenner PG and Brin MF. Neurology 50 (suppl 6), S39-S43 (1998).
4. Chalmers GR, Fisher LJ, Niijima K, et al. Exp Neurol 133, 32-42 (1986).
5. Zhang L, Blanco C, Escobar A et al. Arch Pharm 358 (suppl 2), R558 (1998).
6. Zhang L, Castell A, Avila ME et al. J Neuropathol Exp. Neurol (in press).
7. Backlund EO, Granberg PO, Hamberger B et al. J Neurosurg 62, 169-173 (1985).
8. Madrazo I, Drucker-Colín R, Díaz V et al. N Engl J Med 316, 831-834 (1987).
9. Hirsch EC, Duychaerts C, Jovoy-Agid F et al. Ann Neurol 27, 676-682 (1990).
10. Lindvall O. Trends Neurosci 14, 379-384 (1991)
11. Drucker-Colín R, Verdugo-Díaz L, Morgado-Valle C et al. Arch Med Res 30, 33-39 (1999).
12. Waymire JC, Bennet F, Boehme R et al. J Neurosci Methods 7, 329-351 (1983).
13. McGahon AJ, Martin SJ, Bissonnette RP et al. The end of the (cell) line: methods for the study of apoptosis in vitro. In: Schwartz LM and Osborne BA, eds. Cell Death. San Diego: Academic Press, 153-185.
14. Lai C and Yu PH. Biochem Pharmacol 53, 363-372 (1997).
15. Mena MA, Pardo B, Paino CL et al. NeuroReport 4, 438-440 (1993).
16. Spencer J, Jenner A, Aruoma OI et al. FEBS Lett 353, 246-250 (1994).
17. Graham DG. Mol Pharmacol 14, 633-643 (1978).
18. Olanow CW. Trends Neurosci 16, 439-444 (1993).
19. Ziv I, Zilkha-Falb R, Offen D et al. Movement Disorders 12, 17-23 (1997).
20. Walkinshaw G and Waters CM. J Clin Invest 95, 2458-2464 (1995).
21. Stewart B. J Natl Cancer Inst 86, 1286-1295 (1994).
22. Perry TL, Godin DV and Hansen S. Neurosci Lett 33, 305-310 (1982).